|1.||Lafuente-Lafuente, Carmelo: 4 articles (01/2015 - 04/2006)|
|2.||Boriani, Giuseppe: 4 articles (04/2010 - 01/2002)|
|3.||Bergmann, Jean-François: 3 articles (01/2015 - 04/2006)|
|4.||Aragon, Martin: 3 articles (01/2014 - 10/2013)|
|5.||Trivi, Marcelo: 3 articles (01/2014 - 10/2013)|
|6.||Conde, Diego: 3 articles (01/2014 - 10/2013)|
|7.||Costabel, Juan Pablo: 3 articles (01/2014 - 10/2013)|
|8.||Dorian, Paul: 3 articles (01/2011 - 09/2003)|
|9.||Martignani, Cristian: 3 articles (04/2010 - 01/2002)|
|10.||Biffi, Mauro: 3 articles (04/2010 - 01/2002)|
06/01/1987 - "Furthermore, propafenone caused a marked decrease in peak ventricular rate during atrial fibrillation. "
03/01/1996 - "Furthermore, the percentage decrease of ventricular rate during atrial fibrillation was significantly greater in patients with propafenone (-25 +/- 4% versus -8 +/- 3%, P < 0.01). "
12/15/2002 - "We report a double-blind, multicenter, multinational, placebo-controlled, and well-controlled trial to prove that the sustained-release (SR) formulation of propafenone is superior to placebo in preventing symptoms of paroxysmal atrial fibrillation (AF). "
03/01/2000 - "Propafenone is an effective and safe antiarrhythmic drug for converting paroxysmal and/or recent-onset atrial fibrillation of various origins with a more limited efficacy in chronic atrial fibrillation."
01/01/1995 - "The two drugs were equally effective in converting postoperative atrial fibrillation and/or flutter after 24 h although propafenone was superior within the first hour."
12/01/2012 - "In patients with non-inducible AVNRT, but without complete ventriculo-atrial block, propafenone was more effective in patients with shorter echo zone of tachycardia."
12/01/2012 - "In patients with non-inducible tachycardia, complete ventriculo-atrial block can be used as an electrophysiological predictor of the efficacy of propafenone oral therapy in the prevention of tachycardia. "
12/01/2012 - "Group A had significantly lower incidence of tachycardia than group B (95% vs 70.8%, P=0.038), and complete ventriculo-atrial block predicted the efficacy of propafenone oral therapy in the prevention of tachycardia (sensitivity 87.5%, specificity 52.8%, positive predictive value 95%, negative predictive value 29.2%). "
01/01/1995 - "Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias. "
04/01/1990 - "Seven of the 13 children (53.8%) with ventricular ectopics, all three children with paroxysmal re-entry atrioventricular tachycardia, and two of the three children with paroxysmal atrial tachycardia were treated successfully with propafenone. "
|3.||Cardiac Arrhythmias (Arrythmia)
06/01/1992 - "A younger age, low spontaneous arrhythmia variability, and particularly a low titration dose were the best predictors of the short and long term efficacy of propafenone. "
12/15/2002 - "There was a significant reduction in average heart rate during the first recurrence of symptomatic arrhythmia after day 5 in the low-dose propafenone group compared with placebo. "
08/01/1987 - "In junctional arrhythmia propafenone was certainly effective but unpredictably so (3 good results, 2 fair results, 4 failures). "
11/01/2002 - "Elevated plasma concentration is consistent with better efficacy of propafenone in patients with ventricular arrhythmia."
06/01/1987 - "Electrophysiologic testing identified the patient's arrhythmia, and demonstrated that it improved with intravenous propafenone, a new type 1C antiarrhythmic medication. "
03/01/1986 - "In 19 cases of ventricular tachycardia, propafenone proved to be efficacious in 3 out of 5 cases presenting rapid discharges and in 7 out of 14 patients with continuous arrhythmias, notably those with a catecholaminergic component. "
12/01/1988 - "Propafenone is effective in treating ventricular tachycardia and in suppressing premature ventricular complexes (PVCs). "
11/14/1984 - "Propafenone was also effective in controlling couplets and nonsustained ventricular tachycardia. "
11/01/1990 - "Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time."
10/01/1985 - "Propafenone eliminated all exercise provocable ventricular tachycardia. "
07/01/1994 - "In addition, propafenone is very effective in young patients with supraventricular tachycardia based on enhanced abnormal automaticity. "
06/01/1989 - "In conclusion, propafenone is very effective in the control of paroxysmal supraventricular tachycardia; intravenous propafenone can predict the efficacy of oral therapy."
06/01/1989 - "The authors studied the efficacy of intravenous (IV) (1.5-2 mg/kg) and oral propafenone (450 to 900 mg/day) in 16 patients with paroxysmal, sustained, recurrent supraventricular tachycardia (SVT). "
11/01/2010 - "Propafenone, an antiarrhythmic drug that is effective for treating supraventricular tachycardias, can induce well-known proarrhythmic and systemic adverse effects. "
10/16/1998 - "Thus, propafenone is effective in terminating supraventricular tachycardias and AF in the vast majority of patients. "
|3.||Sotalol (Sotalol Hydrochloride)
|10.||Cytochrome P-450 CYP2D6 (CYP2D6)
|1.||Electric Countershock (Cardioversion)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|4.||Fontan Procedure (Fontan Operation)